Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04760652 · ClinicalTrials.gov registry record · NA
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT04760652 is a NA study that has completed, run by Yale University. The registered enrollment target is 92 participants.
The verdict
NCT04760652, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI). Subjects will be randomized (1:1) to receive CBT (computer-assisted) or TAU alone following esketamine.
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy CBT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04760652
The ClinicalTrials.gov registry entry for NCT04760652 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cognitive Behavioral Therapy CBT is the first listed.
NCT04760652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04760652 about?
NCT04760652 is a clinical study titled "Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention". This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI). Subjects will be randomized (1:1) to receive CBT (computer-assisted) or TAU alone following esketamine.
What is the current status of trial NCT04760652?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2021-03-05. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04760652?
The interventions under investigation include: Cognitive Behavioral Therapy CBT (BEHAVIORAL).
Who is sponsoring clinical trial NCT04760652?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.